Lung Cancer Clinical Trial
Official title:
A Novel Multimodal Intervention for Surgical Prehabilitation of Patients With Lung Cancer: Pilot Study
Verified date | October 2020 |
Source | McGill University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Lung cancer is the second most prevalent cancer in Canada and the leading cause of cancer-related mortality worldwide. Patients diagnosed at earlier (non-metastatic) stages are potential candidates for surgical tumor removal. However, they often present with poor nutritional status and physical function adding to the major catabolic stress imposed by surgery that negatively impacts recovery and survival after surgery. The purpose of this study is to investigate the potential benefits of a prehabilitation program that includes a combined nutritional supplement (whey protein, leucine, vitamin D and omega-3 fatty acids) with exercise and relaxation techniques for 4 weeks before surgery and continued for 8 weeks after surgery on functional pre- and postoperative outcomes, versus standard hospital care (control). Investigators will study whether the prehabilitation program improves physical performance, muscle mass and quality of life in patients undergoing lung cancer resection. The specific objective of this pilot study is to test feasibility and adherence to intervention, and generate pilot data to inform the design of a larger trial.
Status | Terminated |
Enrollment | 34 |
Est. completion date | March 12, 2020 |
Est. primary completion date | March 12, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - adult men and women with NSCLC stages I, II or IIIa, planned for video-assisted thoracic surgery (VATS) or open thoracotomy surgery for cancer resection or exploration. Exclusion Criteria: - prior recent (<3 mo) chemotherapy, comorbidities contraindicating exercise (defined as CPET <10 mL O2/kg/min), walking aids other than a cane, glomerular filtration rate <30 mL/min/m2, allergy to milk or seafoods, chronic use of anti-coagulants, hypercalcemia, hypervitaminosis D, insufficient understanding of English or French language to provide informed consent. All medications and co-morbidities will be recorded. Patients taking vitamin D will continue their supplements; risk of potential overdosing will be monitored by serum 25(OH)D levels >80 nmol/L. Those taking n-3 FA supplements will be asked to withhold during the study. |
Country | Name | City | State |
---|---|---|---|
Canada | Research Institute of the McGill University Health Centre | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
McGill University | MUHC-Montreal General Hospital Foundation, Peri-Operative Program Charitable Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Dietary assessment | Collected using 2 and 3-day food diaries. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Plasma phospholipid n-3 FA profile | Plasma lipids will be extracted with organic solvents, phospholipids isolated on thin-layer chromatography, and FAs methylated for determination by gas chromatography-flame-ionization analysis. Used as an objective measure of adherence to fish oil. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Serum 25(OH)D | Concentrations will be measured by the MUHC-Central Lab. Used as an objective measure of adherence to the supplement. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Inflammation | Will be assessed with serum C-reactive protein (hs-CRP) by MUHC-Central Lab. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Serum albumin | Will be analyzed as standard procedures by the MUHC-Central Lab. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Pre-albumin | Will be analyzed as standard procedures by the MUHC-Central Lab. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Hemoglobin | Will be analyzed as standard procedures by the MUHC-Central Lab. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Exercise tolerance - oxygen consumption | Assessed using cardiopulmonary exercise testing and measuring oxygen consumption at anaerobic threshold and peak exercise | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Exercise tolerance - workload | Assessed by cardiopulmonary exercise testing at anaerobic threshold and peak exercise | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Exercise tolerance - heart rate | Assessed by cardiopulmonary exercise testing and measured at anaerobic threshold and peak exercise | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Pulmonary function (FEV1) | Spirometry standard methods to measure FEV1. | Baseline and 4-week postoperative | |
Other | Pulmonary function (FVC) | Spirometry standard methods to measure FVC. | Baseline and 4-week postoperative | |
Other | Pulmonary function (FEV1/FVC) | Spirometry standard methods to measure the FEV1/FVC ratio. | Baseline and 4-week postoperative | |
Other | Pulmonary function (FEF 25-75%) | Spirometry standard methods to measure FEF 25-75 percent. | Baseline and 4-week postoperative | |
Other | Physical activity | Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire, score 0 - x (no maximum score), higher mean more activity | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Anxiety/depression | Hospital Anxiety and Depression Scale (questionnaire). Scoring for each item ranges from zero to three. A subscale score >8 denotes anxiety or depression. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Other | Nutritional status | Patient-Generated Subjective Global Assessment (PG-SGA). In general, the higher total additive scores upon initial exam correlates with more severely malnourished cases (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished). | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Primary | Feasibility: Recruitment rate | Recruitment rate (measured in percent, compared to expected rates) | Over entire recruitment period (approximately 1 year) | |
Primary | Feasibility: Adherence to intervention | Adherence to exercise and nutritional interventions (measured in percent, compared to expected rates) | Over 12 weeks (4 weeks pre- and 8 weeks post-surgery) | |
Primary | Feasibility: completion of study outcome assessment | Completion of study outcome assessments (measured in percent, compared to expected rates) | Over 12 weeks (4 weeks pre- and 8 weeks post-surgery) | |
Secondary | Functional walking capacity | Six-minute walking test: measured as the distance walked during 6 minutes, along a 20-m corridor, expressed in m) | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Length of hospital stay | Recorded from medical charts | 8-week postoperative | |
Secondary | Post-operative complications | Recorded from medical charts and will be graded by severity following the Clavien-Dindo classification. | 8-week postoperative | |
Secondary | Health related quality of life | Measured by the cumulative score of the 36-item Short Form Health Survey, score 0-100, higher score means better quality of life. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Quality of Life | Measured by cumulative score of the Functional Assessment of Cancer Therapy - Lung questionnaires, score 0-136, higher means better quality of life. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Muscle strength - handgrip | Handgrip strength using hand-held Jamar dynamometer, measured in kg. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Muscle strength - leg | Isokinetic leg strength (knee extension peak torque) using Biodex, measured in N, on the dominant side. | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Muscle volume | Skeletal muscle volume will be measured in the dominant foreleg, using peripheral quantitative CT (pQCT, Stratec XCT2000). | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Muscle radiodensity | Skeletal muscle density will be measured in the dominant foreleg, using peripheral quantitative CT (pQCT, Stratec XCT2000). | Baseline, preoperative, 4-week postoperative and 8-week postoperative | |
Secondary | Body composition | Lean and fat mass will be measured by bioelectrical impedance (InBody 230V) | Baseline, preoperative, 4-week postoperative and 8-week postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|